What this is
- How it works
- HER3-targeted antibody-drug conjugate
- How it’s given
- “SHR-A2009 monotherapy ,SHR-A2009 will be administered intravenously”In the company’s words, NCT06671379 on ClinicalTrials.gov
- Tested for
- Non-small Cell Lung Cancer (3 trials), Advanced Solid Tumors (2 trials), Non-squamous Non-small Cell Lung Cancer
- Main trialPhase 3
- “This study was a randomized, controlled, open-label, multicenter phase III clinical study to compare the efficacy and safety of SHR-A2009 with platinum-based dual-agent chemotherapy in patients with EGFR-mutated advanced or metastatic non-small cell lung cancer who failed EGFR TKI treatment.”In the company’s words, NCT06671379 on ClinicalTrials.gov
- Other names
- SHR-A2009
Other drugs for Non-small Cell Lung Cancer
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- CobimetinibRoche · Phase 2/3
- DivarasibRoche · Phase 3
- EntrectinibRoche · Phase 3
Coming up6
- 30 DecPhase 1 trial completes · ClinicalTrials.gov
- DecPhase 3 trial completes · ClinicalTrials.gov
- 30 Dec 2028Phase 3 trial completes · ClinicalTrials.gov
- 30 Dec 2028Phase 2 trial completes · ClinicalTrials.gov
- Jun 2029Phase 1/2 trial completes · ClinicalTrials.gov
- Nov 2032Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 18 NovStatus changed: Not yet recruiting to Recruiting · ClinicalTrials.gov NCT07863167
Trials9
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Dec 2026 | A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC | |
| Phase 3Not yet recruiting | 30 Dec 2028 | SHR-A2009 Combined With Bevacizumab in the Treatment of Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer : a Randomized Controlled, Open, Multicenter Phase III Study | |
| Phase 3Active, not recruiting | Nov 2032 | A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC | |
| Phase 2Recruiting | 30 Dec 2028 | An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer. | |
| Phase 1/2Recruiting | Jun 2029 | A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors | |
| Phase 1Active, not recruiting | 30 Dec 2026 | A Phase I Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors | |
| Phase 1/2Unknown | Dec 2025 | A Phase IB/II Clinical Study of SHR-A2009 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors | |
| Phase 1/2Unknown | 31 Oct 2026 | Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer | |
| Phase 1Completed | 30 Apr 2024 | The Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026